NCT05048472Completed
East Africa Point of Care Viral Load Study
Implementation of Point of Care HIV Viral Load Monitoring to Improve Viral Load Suppression Among Children, Adolescents and Young People Living With HIV in East Africa
Source: ClinicalTrials.gov · Last updated 1 Jul 2025
Brief summary (registry, in English)
The purpose of EAPoC-VL project is to examine the feasibility, acceptability, and effectiveness of using point of care viral load (PoC VL) monitoring to improve viral load suppression among children, adolescents and young people (age ≤24 years) living with HIV in Kenya, Rwanda, Tanzania and Uganda.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 956 (actual)
- First submitted
- 1 Sept 2021
- Start date
- 19 Aug 2022
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
- Diseases
- HIV
- NCT number
- NCT05048472
What you commit to
- Study type: Interventional
- Participants enrolled: 956
- From 19 Aug 2022 to the primary completion date, 30 Apr 2025
- 7 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any medical conditions that require pausing of ART for more than three months.
- Any medical or other condition in the potential participant or their parent/ guardian that precludes provision of informed consent/ assent or that may hinder achieving study objectives as per investigator's judgement.
Other
- Potential participant already enrolled in another study which may interfere with the study outcome or participation as per investigator's judgement.
- Child, adolescent or young person already enrolled and completed follow up in the current study.
Who the study is looking for
- Age 6 months - 24 years
- Documented evidence of HIV infection
- Receiving ART for treatment of HIV infection for at least 6 months.
- Has had a detectable VL of \>1000 copies/ml in the last 6 months.
- Guardian, parent or legal representative able and willing to give voluntary consent and sign/mark an informed consent document.
- Willing and able to comply with protocol requirements/study procedures.
Age in the registry: 6 months to 24 years · Sex: All · Accepts healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kenya Medical Research Institute Coordinator of this site? Confirm its status | Kisumu | Kenya | Unknown status |
| University of Rwanda Coordinator of this site? Confirm its status | Kigali | Rwanda | Unknown status |
| Management and Development for Health Coordinator of this site? Confirm its status | Dar es Salaam | Tanzania | Unknown status |
| National Institute of Medical Research Coordinator of this site? Confirm its status | Dar es Salaam | Tanzania | Unknown status |
| Kilimanjaro Clinical Research Institute Coordinator of this site? Confirm its status | Moshi | Tanzania | Unknown status |
| Unhro/ Uvri Coordinator of this site? Confirm its status | Entebbe | Uganda | Unknown status |
| MRC/UVRI and LSHTM Coordinator of this site? Confirm its status | Entebbe | Uganda | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.